Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation

European Journal of Medical Research

Volumn 12, Issue 11, 2007, Pages 556-562

  Loppow, D ^a   Huland, E ^b   Heinzer, H ^b   Gronke L ^a   Magnussen, H ^a   Holz, O ^a   Jörres, Rudolf A ^a,c  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bronchial hyperreactivity; Eosinophils; Immunotherapy; Induced sputum; Lung function; Lymphocytes; Nitric oxide; Renal cell carcinoma

Indexed keywords

CYTOKINE; METHACHOLINE; NITRIC OXIDE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; RESPIRATORY TRACT INFLAMMATION; SEX DIFFERENCE; SPUTUM ANALYSIS; T LYMPHOCYTE;

ADMINISTRATION, INHALATION; ANTINEOPLASTIC AGENTS; ASTHMA; BREATH TESTS; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CARCINOMA, RENAL CELL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; KIDNEY NEOPLASMS; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITRIC OXIDE; RECOMBINANT PROTEINS; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 36148936323     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
2. Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H: Home therapy with recombinant interleukin-2 and interferon alpha 2 b in advanced human malignancies. Lancet 1990;335:1509-1512.
3. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal-cell carcinoma using highdose bolus interleukin-2. JAMA 1994;271:907-913.
4. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-1935.
5. Heinzer H, Mir TS, Huland E, Huland H: Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999;17:3612-3620.
6. Huland E, Heinzer H, Huland H, Yung R: Overview of interleukin-2 inhalation therapy. Cancer J Sci Am 2000;6 (suppl 1):S104-112.
7. Lorenz J, Wilhelm K, Kessler M, Peschel C, Schwulera U, Lissner R, Struff WG, Huland E, Huber C, Aulitzky WE: Phase I trial of inhaled natural interleukin-2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics and biological effects. Clin Cancer Res 1996;2:1115-1122.
8. Huland E, Heinzer H, Huland H: High risk patients with with pulmonary metastases of renal cell carcinoma: safety and efficacy of inhaled interleukin-2 compared to systemic IL-2 [Abstract]. Eur Urol 2003;l(Suppl. 2): 98A.
9. Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B: Clinical and immunological effects of recombinant intedeukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561-2567.
10. Zissel G, Aulitzky WE, Lorenz J, Huber C, Müller-Quernheim J: Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immunother 1996;42:122-126.
11. Ardizzoni A, Bonavia M, Viale M, Baldini E, Meteu C, Verna A, Ferrini S, Cinquegrana A, Molinari S, Mariani GL, et al.: Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer 1994;73:1353-1360.
12. Sedgwick JB, Frick WE, Sondel PM, Hank JA, Borden E, Busse WW: The appearance of hypodense eosinophils during interleukin-2 treatment. J Allergy Clin Immunol 1990;85:557-566.
13. van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, Dennin R, Abrams JS: Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991; 78: 1538-1544.
14. Durham SR, Till SJ, Corrigan CJ: T lymphocytes in asthma: bronchial versus peripheral responses. J Allergy Clin Immunol 2000;106:S221-226.
15. Salvi SS, Babu KS, Holgate ST: Is asthma really due to a polarized T cell response toward a helper T cell type 2 phenotype? Am J Respir Crit Care Med 2001;164:1343-1346.
16. Jayaram, Parameswaran K, Sears MR, Hargreave FE: Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 2000;16:150-158.
17. Kharitonov SA, Barnes PJ: Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163: 1693-1722.
18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society, Eur Respir J 1993;16(suppl):5-40.
19. Huland E, Heinzer H, Mir TS, Huland H: Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. Cancer J Sci Am 1997;3:S98-105.
20. Jörres RA, Nowak D, Kirsten D, Grönke L, Magnussen H. A short protocol for methacholine provocation testing adapted to the Rosenthal-Chai dosimeter technique. Chest 1997;111:866-869.
21. Holz O, Jörres RA, Koschyk S, Speckin P, Welcker L, Magnussen H. Changes in sputum composition during sputum induction in healthy and asthmatic subjects. Clin Exp Allergy 1998;28:284-292.
22. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the ordine and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 200515;171:912-930.
23. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC: Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995;86:1408-1409.
24. Grönke L, Kanniess F, Holz O, Jörres RA, Magnussen H: The relationship between airway hyperresponsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy 2002;165:57-63.
25. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST: Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 1995;151:879-886.
26. Kharitonov SA, Yates D, Barnes PJ: Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J 1995;8:295-297.
27. Laitinen LA, Elkin RB, Empey DW, Jacobs L, Mills J, Nadei JA: Bronchial hyperresponsiveness in normal subjects during attenuated influenza virus infection. Am Rev Respir Dis 1991;143:358-361. Comment in: Am Rev Respir Dis 1991;144:1422-1423.
28. Barzrca S, Meydan N, Barklak A: Prevention of interleukin-2-induced severe bronchospasm with salbutamol. J Aerosol Med 2003;16:183-184.
29. Holzer K, Anderson SD, Chan HK, Douglass J: Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med 2003;167:534-537.
30. Renzi PM, Sapienza S, Du T, Wang NS, Martin JG: Lymphokine-induced airway hyperresponsiveness in the rat. Am Rev Respir Dis 1991;143:375-379.
31. Renzi PM, Sapienza S, Waserman S, Du T, Olivenstein R, Wang NS, Martin JG: Effect of interleukin-2 on the airway response to antigen in the rat. Am Rev Respir Dis 1992;146:163-169.
32. Tompkins MB, Novomey C, Grindem CB, Page R, English R, Nelson P, Tompkins WA: Human recombinant interleukin-2 induces maturation and activation signals for feline eosinophils in vivo. J Leukoc Biol 1990;48:531-540.
33. Levi-Schäffer F, Barkans J, Newman TM et al.: Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 1996;87:155-161.
34. H1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995; 12:477-487.
35. Lanz MJ, Leung DY, McCormick DR, Harbeck R, Szefler SJ, White CW: Comparison of exhaled nitric oxide, serum eosinophilic cationic protein, and soluble interleukin-2 receptor in exacerbations of pediatric asthma. Pediatr Pulmonol 1997;24:305-311.
36. Motojima S, Ogata H, Tateishi K, Kushima A, Yamai T, Fukuda T, Makino S: Soluble interleukin-2 receptor in sputum from patients with bronchial asthma. Arerugi 1993;42:162-166.
37. Enokihara H, Furusawa S, Nakakubo H, Kajitani H, Nagashima S, Saito K, Shishido H, Hitoshi Y, Takatsu K, Noma T, et al.: T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood 1989;73:1809-1813.
38. Ishimitsu T, Torisu M: An eosinophil chemotactic lymphokine in the supernatant of lymphokine-activated killer (LAK) cell culture: relationship to interleukin-5. J Surg Res 1993;55:307-313.
39. Nakajima H, Nakao A, Watanabe Y, Yoshida S, Iwamoto I: IFN-alpha inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue. J Immunol 1994; 153:1264-1270.
40. Huland E, Huland H: Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 1992;118:463-467.
41. Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993;54:8-15. Erratum in: Int J Cancer 1993;54:887
42. Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, Zhu J, Paul WE: Interleukin 2 plays a central role in Th2 differentiation. PNAS 2004;101:3880-3885.
43. Thijs LG, Hack CE, Strack van Schiindel RJ, Nuijens JH, Wolbink BJ, Eerenberg-Belmer AJ, Van der Vall H, Wagstaff J: Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol 1990;144:2419-2424.
44. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000;406:998-1001.
45. Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, Kohl J, Wahl L, Kuperman D, Germer S, Aud D, Peltz G, Wills-Karp M: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1:221-226. Comment in: Nat Immunol 2000;1:190-192.